[A modern therapeutic strategy in Ph-positive chronic myeloleukemia]

N D Khoroshko; A G Turkina; V S Zhuravlev; M A Sokolova; I N Mikhaĭlova; A V Zakharova; E V Domracheva; E A Semenova

[A modern therapeutic strategy in Ph-positive chronic myeloleukemia]

Ter Arkh. 1996;68(7):22-7.

[Article in Russian]

Authors

N D Khoroshko, A G Turkina, V S Zhuravlev, M A Sokolova, I N Mikhaĭlova, A V Zakharova, E V Domracheva, E A Semenova

PMID: 8928067

Abstract

The aim of this paper was to show the validity of programmed treatment of chronic myeloid leukemia (CML) patients regarding the risk group. In a group of low CML risk monochemotherapy (myelosan or hydroxyurea) was applied. In a group of moderate or high CML risk cytostatic therapy was performed in two variants: as monotherapy and polychemotherapy. Of 112 patients with CML, 50 received cytostatics plus long-term course of interferon-alpha. The combined treatment was well tolerated.

Publication types

English Abstract

MeSH terms

Adolescent
Adult
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Busulfan / administration & dosage
Chronic Disease
Combined Modality Therapy
Female
Humans
Hydroxyurea / administration & dosage
Interferon Type I / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged
Recombinant Proteins
Remission Induction
Risk Factors
Time Factors

Substances

Antineoplastic Agents, Alkylating
Interferon Type I
Recombinant Proteins
Busulfan
Hydroxyurea